

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(2) CHANGE OF COMPOSITION OF BOARD COMMITTEES; AND
(3) APPOINTMENT OF CHIEF FINANCIAL CONTROLLER**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Group Limited (the “**Company**”) hereby announces that Ms. Yang Huimin (“**Ms. Yang**”) has tendered her resignation as an independent non-executive Director with effect from 20 October 2026 in order to assume the role of chief financial controller of the Company. Ms. Yang has confirmed that she has no disagreement with the Board and that there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company. The Board would like to express its appreciation to Ms. Yang for her valuable contributions to the Company during her tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Jiang Li (“**Ms. Jiang**”) has been appointed as an independent non-executive Director with effect from 20 October 2026. The biographical details of Ms. Jiang are set out below:

Ms. Jiang Li, aged 43, has been an associate professor at the Shanghai International College of Intellectual Property, Tongji University, and deputy director of the Research Centre for Pharmaceutical Law and Intellectual Property since May 2019. Ms. Jiang obtained a Bachelor of Science degree in Biotechnology from the University of Science and Technology Beijing in July 2006, a Juris Master degree from Shandong University in June 2009, and a Doctor of Philosophy degree in Law from Bangor University in the United Kingdom in March 2015. Ms. Jiang obtained the legal professional qualification in 2008 and qualified as a patent agent in 2016.

Ms. Jiang's principal research areas include intellectual property law, pharmaceutical and health law, law and ethics in the field of life sciences and technology, and science and technology policy and management. Ms. Jiang served as a lecturer at the Kenneth Wang School of Law, Soochow University, from May 2015 to April 2019. From July 2024 to December 2024, Ms. Jiang was a visiting scholar at the Centre for Ethics and Law in the Life Sciences (Durham CELLS), Durham University, in the United Kingdom. Ms. Jiang currently also serves as an expert in the Shanghai Foreign-related Legal Talent Pool, a specially appointed professor of the Shanghai courts, a specially invited consulting expert of the Yangpu District People's Court, a consulting expert under the "Feng Fa Shang Xian" programme of the Fengxian District People's Court, a member of the Ethics Committee of the Stomatological Hospital of Tongji University, and an arbitrator of the Nantong Arbitration Commission. She is also a council member of the Professional Committee on Biomedical Intellectual Property of the China Health Law Society, the Yangtze River Delta Biomedical Industry Alliance and the Shanghai Society of Life Law, as well as a member of the China Intellectual Property Law Society, the China Health Law Society and the Shanghai Intellectual Property Law Research Association. Ms. Jiang previously served as a part-time lawyer at Boss & Young Attorneys-At-Law from 2022 to 2025 and as a council member of the Shanghai Baoshan Baozhi Intellectual Property Innovation and Transformation Research Institute from 2022 to 2025.

Ms. Jiang has received various honours, including the 2022 Rosalind Franklin Society Award in Science and recognition as an Intellectual Property Backbone Talent of Jiangsu Province in 2017. She also received funding from the China Scholarship Council to pursue her doctoral studies, as well as the Bangor University 125th Anniversary Scholarship and the Law School Scholarship.

Ms. Jiang has an extensive record of research and publication in the fields of intellectual property law, life sciences and technology law, and ethical governance. She has published academic monographs in these fields and has led multiple research projects, including projects under the National Social Science Fund, the National Judicial and Rule of Law Theory Research Programme, the China Law Society and the Shanghai Philosophy and Social Sciences Planning Programme. Her academic papers have been published in a number of core journals in the PRC and overseas. Ms. Jiang also serves as a reviewer for a number of international and PRC academic journals.

Ms. Jiang has entered into a letter of appointment with the Company for a period of 3 years commencing from 20 October 2026. Her appointment is subject to retirement by rotation and re-election in accordance with the Bye-laws of the Company. Ms. Jiang is entitled to a director's fee of HK\$100,000 per annum, determined by the Board upon the recommendation of the remuneration committee of the Board (the "**Remuneration Committee**"), having regard to her experience, knowledge, qualifications, duties and responsibilities and the prevailing market conditions.

Save as disclosed above, Ms. Jiang (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Jiang has confirmed (i) her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) that there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, there is no other information relating to Ms. Jiang that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Ms. Jiang for joining the Board.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following the resignation of Ms. Yang and the appointment of Ms. Jiang as an independent non-executive Director, Ms. Yang has ceased to be the chairman of the Remuneration Committee and a member of each of the audit committee of the Board (the “**Audit Committee**”) and the nomination committee of the Board (the “**Nomination Committee**”), while Ms. Jiang has been appointed as the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee.

APPOINTMENT OF CHIEF FINANCIAL CONTROLLER

The Board is also pleased to announce that Ms. Yang has been appointed as the chief financial controller of the Company with effect from 1 November 2026. The biographical details of Ms. Yang are set out below:

Ms. Yang Huimin, aged 49, obtained a bachelor's degree in economics from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) in 1998 and a Master's degree of Management in Nanjing University in 2001. Ms. Yang is a non-practising member of the Chinese Institute of Certified Public Accountants (CPA) and holds the Chartered Financial Analyst qualification (CFA). Ms. Yang has extensive experience in company finance and listed company operations. In 2010 – 2014, she joined COFCO Property (Group) Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code of SZ000031) and successively became the vice general manager of the financial department, the general manager of the operation department and the vice general manager of the Shenzhen Centre City Company. In 2014 – 2015, Ms. Yang was appointed as the chief financial officer and secretary of the board of directors of COFCO & CM (Shenzhen) Grain Electronic Trading Centre Co., Ltd.. She has been the independent non-executive Director of the Company from 18 June 2016 to 7 May 2018. She was re-appointed as independent non-executive Director of the Company on 30 December 2024 and resigned on 20 October 2026.

The Board would like to express its warm welcome to Ms. Yang on taking up her new role within the Company.

By order of the Board
China Health Group Limited
Cao Xu
Chairman of the Board and Executive Director

Hong Kong, 20 October 2026

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Wu Hui, Mr. Li Hongyi and Ms. Jiang Li.